고지혈증 치료 가이드라인
Lipid-Lowering Therapy Guidelines
이상학,
소속 상세정보
이상학 ( Lee Sang-Hak )
연세대학교 의과대학 세브란스병원 심장내과
Abstract
The major guidelines for lipid-lowering therapy (LLT) have been revised recently. Although “higher cardiovascular risk-aggressive LLT with greater absolute clinical benefit” is the main idea underlying all guidelines, there are some differences in the details among them. The US guidelines recommend pharmacological LLT based on a patient’s risk category, independently of their low-density lipoprotein-cholesterol (LDL-C) level. However, the European and Korean guidelines consider the patient’s risk category and LDL-C at the same time. Lifestyle modifications are suggested in parallel in all guidelines. The newest US guidelines have characteristically revived target LDL-C values in some patient groups and indications for non-statin drugs (ezetimibe and PCSK9 inhibitors), whereas the European and Korean guidelines have maintained target LDL-C values as usual. It is universally accepted that statins are the first-line agent. Adding ezetimibe, bile acid sequestrants, or PCSK9 inhibitors is recommended as a second line treatment. Appreciating the trend and background of the newest LLT guidelines will be essential to maximize cardiovascular prevention in patients.
키워드
콜레스테롤; 죽상동맥경화증; 치료제; 지단백
Cholesterol; Atherosclerosis; Therapeutics; Lipoproteins
원문 및 링크아웃 정보
등재저널 정보